United Therapeutics Co. (NASDAQ:UTHR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

United Therapeutics Co. (NASDAQ:UTHR) has received a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $357.17.

A number of research analysts recently issued reports on the company. Jefferies Financial Group lifted their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. UBS Group upped their price target on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Finally, TD Cowen raised their price objective on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 7,785 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at $947,597.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now owns 2,615 shares in the company, valued at approximately $947,597.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $40,622.40. The disclosure for this sale can be found here. Insiders have sold a total of 111,252 shares of company stock valued at $36,939,427 in the last 90 days. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Norges Bank bought a new position in United Therapeutics during the fourth quarter valued at approximately $100,519,000. LSV Asset Management lifted its stake in shares of United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Swedbank AB bought a new stake in United Therapeutics in the first quarter worth $97,316,000. Nordea Investment Management AB increased its position in United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares during the last quarter. Finally, Avidity Partners Management LP bought a new position in United Therapeutics during the fourth quarter valued at about $52,158,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Up 0.5 %

UTHR stock opened at $359.51 on Friday. The firm’s 50-day moving average is $340.91 and its two-hundred day moving average is $294.15. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $15.99 billion, a price-to-earnings ratio of 17.00, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $366.08.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same quarter last year, the company earned $5.24 earnings per share. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, analysts forecast that United Therapeutics will post 24.84 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.